BMY
Income statement / Annual
Last year (2024), Bristol-Myers Squibb Company's total revenue was $48.30 B,
an increase of 7.32% from the previous year.
In 2024, Bristol-Myers Squibb Company's net income was -$8.95 B.
See Bristol-Myers Squibb Company,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$48.30 B |
$45.01 B |
$46.16 B |
$46.39 B |
$42.52 B |
$26.15 B |
$22.56 B |
$20.78 B |
$19.43 B |
$16.56 B |
| Cost of Revenue |
$20.87 B
|
$19.65 B
|
$19.67 B
|
$19.62 B
|
$20.82 B
|
$8.90 B
|
$6.49 B
|
$5.82 B
|
$4.93 B
|
$3.75 B
|
| Gross Profit |
$27.43 B
|
$25.36 B
|
$26.49 B
|
$26.76 B
|
$21.70 B
|
$17.25 B
|
$16.08 B
|
$14.96 B
|
$14.50 B
|
$12.81 B
|
| Gross Profit Ratio |
0.57
|
0.56
|
0.57
|
0.58
|
0.51
|
0.66
|
0.71
|
0.72
|
0.75
|
0.77
|
| Research and Development Expenses |
$9.78 B
|
$9.21 B
|
$9.41 B
|
$9.53 B
|
$9.56 B
|
$5.95 B
|
$5.13 B
|
$4.97 B
|
$4.41 B
|
$4.04 B
|
| General & Administrative Expenses |
$6.37 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$1.50 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.87 B
|
$7.68 B
|
$7.81 B
|
$7.69 B
|
$7.65 B
|
$4.86 B
|
$4.55 B
|
$4.75 B
|
$4.91 B
|
$4.83 B
|
| Other Expenses |
$127.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$17.77 B
|
$16.89 B
|
$17.22 B
|
$17.22 B
|
$17.21 B
|
$10.81 B
|
$9.68 B
|
$9.72 B
|
$9.32 B
|
$8.87 B
|
| Cost And Expenses |
$38.64 B
|
$36.53 B
|
$36.89 B
|
$36.85 B
|
$38.03 B
|
$19.71 B
|
$16.17 B
|
$15.54 B
|
$14.25 B
|
$12.62 B
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$1.95 B
|
$1.17 B
|
$1.23 B
|
$1.33 B
|
$1.42 B
|
$656.00 M
|
$183.00 M
|
$196.00 M
|
$167.00 M
|
$184.00 M
|
| Depreciation & Amortization |
$9.60 B
|
$9.76 B
|
$10.28 B
|
$10.69 B
|
$10.38 B
|
$1.75 B
|
$637.00 M
|
$789.00 M
|
$382.00 M
|
$376.00 M
|
| EBITDA |
$3.17 B |
$19.37 B |
$19.22 B |
$20.12 B |
$4.93 B |
$7.38 B |
$6.79 B |
$6.12 B |
$6.46 B |
$2.64 B |
| EBITDA Ratio |
0.07
|
0.43
|
0.42
|
0.43
|
0.12
|
0.28
|
0.3
|
0.29
|
0.33
|
0.16
|
| Operating Income Ratio |
0.2
|
0.19
|
0.2
|
0.21
|
0.11
|
0.25
|
0.28
|
0.25
|
0.27
|
0.24
|
| Total Other Income/Expenses Net |
-$18.04 B
|
-$32.00 M
|
-$1.56 B
|
-$1.44 B
|
-$11.36 B
|
-$1.46 B
|
-$426.00 M
|
-$108.00 M
|
$736.00 M
|
-$1.86 B
|
| Income Before Tax |
-$8.38 B
|
$8.44 B
|
$7.71 B
|
$8.10 B
|
-$6.87 B
|
$4.98 B
|
$5.97 B
|
$5.13 B
|
$5.92 B
|
$2.08 B
|
| Income Before Tax Ratio |
-0.17
|
0.19
|
0.17
|
0.17
|
-0.16
|
0.19
|
0.26
|
0.25
|
0.3
|
0.13
|
| Income Tax Expense |
$554.00 M
|
$400.00 M
|
$1.37 B
|
$1.08 B
|
$2.12 B
|
$1.52 B
|
$1.02 B
|
$4.16 B
|
$1.41 B
|
$446.00 M
|
| Net Income |
-$8.95 B
|
$8.03 B
|
$6.33 B
|
$6.99 B
|
-$9.00 B
|
$3.44 B
|
$4.92 B
|
$1.01 B
|
$4.46 B
|
$1.57 B
|
| Net Income Ratio |
-0.19
|
0.18
|
0.14
|
0.15
|
-0.21
|
0.13
|
0.22
|
0.05
|
0.23
|
0.09
|
| EPS |
-4.41 |
3.88 |
2.97 |
3.15 |
-3.98 |
2.02 |
3.03 |
0.61 |
2.67 |
0.97 |
| EPS Diluted |
-4.41 |
3.86 |
2.95 |
3.12 |
-3.98 |
2.01 |
3.03 |
0.61 |
2.65 |
0.97 |
| Weighted Average Shares Out |
$2.03 B
|
$2.07 B
|
$2.13 B
|
$2.22 B
|
$2.26 B
|
$1.71 B
|
$1.63 B
|
$1.65 B
|
$1.67 B
|
$1.67 B
|
| Weighted Average Shares Out Diluted |
$2.03 B
|
$2.08 B
|
$2.15 B
|
$2.25 B
|
$2.26 B
|
$1.71 B
|
$1.64 B
|
$1.65 B
|
$1.68 B
|
$1.68 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
